Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Olive

Showing results (251-260 of 276) with videos related to

Pageof 28
Sort By:
Frontiers in Oncology|October 10, 2022
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?Daniele Fanale, Lidia Rita Corsini, Chiara Brando, et al.
Cancer Research|February 27, 2009
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcomeMichael Gobert, Isabelle Treilleux, Nathalie Bendriss-Vermare, et al.
Blood Advances|October 23, 2020
ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cellsFlorent Amatore, Nicolas Ortonne, Marc Lopez, et al.
Oncotarget|September 20, 2019
Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Human Pathology|April 18, 2017
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patientsLuc Xerri, Sarah Huet, Jeffrey M Venstrom, et al.
Oncotarget|May 27, 2017
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Cancer Research Communications|October 23, 2024
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing TumorsMarc Lopez, Emerence Crompot, Emmanuelle Josselin, et al.
Cancer Research|April 15, 2022
Editor's Note: ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing AutophagyYosra Messai, Muhammad Zaeem Noman, Meriem Hasmim, et al.
Cancer Research|October 10, 2014
ITPR1 protects renal cancer cells against natural killer cells by inducing autophagyYosra Messai, Muhammad Zaeem Noman, Meriem Hasmim, et al.
Oncoimmunology|September 14, 2016
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM WorkshopRoch Houot, Philippe Gaulard, Robert Schreiber, et al.
Pageof 28

Showing results (251-260 of 276) with videos related to

Sort By:
Pageof 28
Frontiers in Oncology|October 10, 2022
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?Daniele Fanale, Lidia Rita Corsini, Chiara Brando, et al.
Cancer Research|February 27, 2009
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcomeMichael Gobert, Isabelle Treilleux, Nathalie Bendriss-Vermare, et al.
Blood Advances|October 23, 2020
ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cellsFlorent Amatore, Nicolas Ortonne, Marc Lopez, et al.
Oncotarget|September 20, 2019
Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Human Pathology|April 18, 2017
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patientsLuc Xerri, Sarah Huet, Jeffrey M Venstrom, et al.
Oncotarget|May 27, 2017
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Cancer Research Communications|October 23, 2024
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing TumorsMarc Lopez, Emerence Crompot, Emmanuelle Josselin, et al.
Cancer Research|April 15, 2022
Editor's Note: ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing AutophagyYosra Messai, Muhammad Zaeem Noman, Meriem Hasmim, et al.
Cancer Research|October 10, 2014
ITPR1 protects renal cancer cells against natural killer cells by inducing autophagyYosra Messai, Muhammad Zaeem Noman, Meriem Hasmim, et al.
Oncoimmunology|September 14, 2016
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM WorkshopRoch Houot, Philippe Gaulard, Robert Schreiber, et al.
Pageof 28